
Purplz 100mg injection
Salt Composition: Bendamustine
Expiry Date: 01/2028
Inclusive of all taxes
1 injection
About The Product
- Chronic Lymphocytic Leukaemia (CLL)
- Non-Hodgkin’s Lymphoma (NHL)
- Multiple Myeloma
Purplz 100mg Injection is an anticancer medicine that belongs to the class of alkylating agents. It is prescribed to treat blood and marrow cancer, such as chronic lymphocytic leukaemia, non-Hodgkin lymphomas, and multiple myeloma. Bendamustine is the main component of this medicine. It slows down the growth of cancer cells in the body by damaging the DNA and RNA of cancer cells.
Side Effects
Purplz 100mg injection may cause some side effects that vary from one patient to another. Most side effects do not require any medical attention and disappear as your body adjusts to the medicine.
Common side effects include:
- Fever
- Chills
- Cough
- Infection
- Pale skin
- Weakness
- Irregular heartbeat
- Chest pain
- Breathing problem
- Swelling in the face and the leg
- Itching
- Rash
- Hives
- Night sweats
- Dry skin
- Joint pain
Contact your doctor immediately if you experience any severe or unusual side effects.
How To Use
- Purplz 100mg injection is given by a doctor or trained nurse under strict medical supervision.
- It is not self-administerable.
- Dosage and duration of the treatment are determined by the doctor as per the patient's health condition.
Safety Advice
Missed Doses
- If you missed a dose, then do not take the missed dose at the time of the next dose.
- Consult the doctor soon for the missed dose.
FAQs
Purplz 100mg injection is used in the treatment of blood cancer, non-Hodgkin lymphoma, and Purplz 100mg injection is used in the treatment of chronic lymphocytic leukaemia, non-Hodgkin lymphoma, and multiple myeloma.
Reference
1. Lalic, H., Aurer, I., Batinic, D., Visnjic, D., Smoljo, T., & Babic, A.
(2022). Bendamustine: A review of pharmacology, clinical use and immunological effects.
Oncology reports, 47(6), 114- https://pubmed.ncbi.nlm.nih.gov/35506458/ 2. Kahl, B.
S., Bartlett, N. L., Leonard, J.
P., Chen, L., Ganjoo, K., Williams, M. E., ... & Cheson, B.
D. (2010).
Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphoma: results from a multicenter study. Cancer: Interdisciplinary International Journal of the American Cancer Society, 116(1), 106-114 - https://pubmed.ncbi.nlm.nih.gov/19890959/ 3.
Gentile, M., Vigna, E., Recchia, A. G., Morabito, L., Mendicino, F., Giagnuolo, G., & Morabito, F.
(2015). Bendamustine in multiple myeloma.
European journal of haematology, 95(5), 377-388. 4.
Kalaycio, M. (2009).
Bendamustine: a new look at an old drug. Cancer, 115(3), 473-479 - https://pubmed.ncbi.nlm.nih.gov/19117340/ 5.
Barman Balfour, J. A., & Goa, K.
L. (2001).
Bendamustine. Drugs, 61(5), 631-638.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.jpeg%3FupdatedAt%3D1763121181831&w=128&q=75)
